Breast Cancer
U.S. FDA approves Herceptin for adjuvant treatment of HER2-positive node-positive breast cancer
Published in Cancer Weekly, December 19th, 2006
The FDA approval was based on data from an interim joint analysis of more than 3,500 patients enrolled in two Phase III clinical trials. These results showed that the addition of Herceptin to standard adjuvant therapy significantly reduced the risk of breast cancer recurrence, the primary endpoint of the studies, by 52% (or a hazard ratio of 0.48) in women with HER2-positive breast cancer, compared...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-12-19)
More Articles from Cancer Weekly
- Cancer Therapy
Chemotherapy temporarily affects the structures of the human brain - Cancer Therapy
Octogenarians are not too old for prostate cancer surgery - Cancer Gene Therapy
Data on cancer gene therapy described by researchers at Medical University of South Carolina, Department of Microbiology - Cancer Gene Therapy
Data on cancer gene therapy detailed by researchers at Ben-Gurion University, Department of Clinical Pharmacology - Cancer Gene Therapy
Data on cancer gene therapy discussed by researchers at University of Washington, Department of Medicine - Cancer Gene Therapy
Data on cancer gene therapy reported by researchers at National Tsing-Hua University - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
